Capricor Therapeutics Investors Urged to Join Class Action Lawsuit for Securities Fraud

Class Action Lawsuit for Capricor Therapeutics Investors

The Schall Law Firm, known for its national focus on shareholder rights, has made a critical announcement for investors in Capricor Therapeutics, Inc. This comes in light of a collective legal action involving allegations of securities fraud. The lawsuit is centered on violations of the Securities Exchange Act of 1934, and it has become essential for affected shareholders to take note.

Overview of the Lawsuit

According to the announcement, the class action lawsuit is aimed against Capricor Therapeutics, with accusations that include breaches of §§10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. Investors who bought stocks between October 9, 2024, and July 10, 2025, might be eligible to participate in this legal action. Specifically, those who have suffered financial losses during this period are encouraged to contact the Schall Law Firm by September 15, 2025, to explore their rights.

What Investors Should Know

The filed complaint indicates that Capricor Therapeutics made misleading assertions about their drug candidate, deramiocel. The company communicated optimistic advancements toward obtaining FDA approval, including a mid-cycle review that reportedly was devoid of significant deficiencies. They also hinted at the planning of an advisory committee meeting. However, contrary to these positive claims, it appears they were concealing detrimental data from the Phase 2 HOPE-2 trial.

This juxtaposition between Capricor’s public statements and the reality of their drug development process led to accusations of securities fraud. When investors eventually discovered the truth about Capricor’s situation, those who had purchased its securities faced substantial monetary damages.

The Importance of Taking Action

Investors who seek to recover losses now have an opportunity to join the class lawsuit. The Schall Law Firm has provided a straightforward platform for interested shareholders to sign up, ensuring that they are included in future proceedings. For investors facing losses or seeking further information, direct contact with Brian Schall is encouraged. He can be reached at the firm's Los Angeles office or through the firm's official website.

Representation Status

It is crucial to note at this point that the class action has not yet received certification. Until such time, shareholders are not represented by an attorney and decisions on participation hinge on individual investor actions. Those choosing to remain passive will retain their status as absent class members, which means they would not benefit from any potential recovery from this lawsuit.

Conclusion

The situation surrounding Capricor Therapeutics serves as a potent reminder of the volatility and risks inherent in securities investment. For shareholders, the ongoing class action provides a pathway to seek redress for potential financial missteps caused by misleading corporate communications. Investors interested in joining this legal effort should proceed with prompt action to ensure their voices are heard and their rights are protected.

As the story unfolds, the clarity regarding Capricor’s operations and the veracity of its past statements will be closely monitored, providing both cautionary lessons and hopeful pathways for investors.